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1. Introduction 
The discovery of leptin in 1994 provoked the interest in the adipose tissue which was no 
longer considered as an inert tissue storing energy in the form of triglycerides but as the 
greatest endocrine organ in human body [1, 2]. As a growing number of people suffer from 
obesity and metabolic syndrome, understanding the mechanisms by which various 
hormones and neurotransmitters have influence on energy balance, weight control and 
insulin resistance has been a subject of intensive research.  
The regulation of appetite and feeding is a homeostatic mechanism. A powerful and 
complex physiological system exists to balance energy intake and expenditure, in order that 
sufficient energy is available and body weight remains stable [2, 3]. This system is composed 
of both afferent signals and efferent effectors. A large number of factors originating 
throughout the body send afferent signals to a smaller number of functional centers in the 
central nervous system (CNS), that then mediate interactions with efferent pathways to 
regulate energy expenditure and energy intake [4]. Thus, central circuits in the brain rely on 
peripheral signals indicating satiety levels and energy stores, as well as higher cortical 
factors such as emotional and reward pathways [5].  
There are numerous peptides involved in the regulation of energy homeostasis, some of 
which are produced centrally and others peripherally in the gastrointestinal tract (GI), with 
some produced at both locations. These peptides are known as members of the ‘gut-brain 
axis’ [6]. Since the discovery of secretin, which was confirmed to stimulate pancreatic 
exocrine secretion, more than 40 other GI tract hormones have been discovered. 
Anticipation of a meal and the presence of food in the stomach and the small intestine 
stimulate secretion of many of these hormones from the gut through mechanical and 
chemical stimuli. These signals are involved in the initiation of food intake as well as 
termination of meals [7]. However, many of the same hormones are also expressed in the 
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CNS, acting to translate metabolic information between the GI tract and the brain [8]. In 
normal subjects, body weight is tightly regulated despite day-to-day variations in food 
intake and energy expenditure. Obesity is due to a state in which energy intake exceeds 
energy expenditure over a prolonged period of time. In humans it is also of note that 
psychological and emotional factors can drive food intake in excess of actual need [7]. 
In summary, signals relaying information such as the nutritional and energy status of the 
body converge within the CNS. Thus, CNS mediates energy balance in the body, the 
hypothalamus playing a main role in this process. The arcuate nucleus (ARC) is a key 
hypothalamic nucleus in the regulation of appetite and is involved in integrating peripheral 
satiety and adiposity signals via orexigenic and anorexigenic neuropeptide transmission to 
other hypothalamic and extrahypothalamic brain regions [9]. Proximity of ARC to the 
median eminence and the fact that it is not fully insulated from the circulation by the blood 
brain barrier makes it strategically positioned to integrate the great number of peripheral 
signals controlling food intake [5]. There are two major neuronal populations in the ARC 
implicated in the regulation of feeding. One population co-expresses Neuropeptide Y (NPY) 
and agouti-related protein (AgRP) and increases food intake. The second population of 
neurons co-expresses cocaine- and amphetamine-related transcript (CART) and pro-
opiomelanocortin (POMC), the precursor to the melanocortin receptor agonist, α-
melanocyte-stimulating hormone (-MSH), and inhibits food intake. Neuronal projections 
from these two populations then communicate with other hypothalamic areas involved in 
appetite regulation such as the paraventricular nucleus (PVN), ventromedial nucleus 
(VMN), dorsomedial nucleus (DMN) and lateral hypothalamic area (LHA) [10].  
Receptors for leptin and insulin are expressed on both of these types of neurons, suggesting 
that they are responsive to circulating levels of these hormonal signals, acting as effectors for 
altering food intake in response to variations in energy balance as indicated by body 
adiposity [11]. Leptin is secreted by adipocytes and circulates at concentrations proportional 
to fat mass. Restriction of food intake for a relatively longer period, results in a supression of 
leptin levels, which can be reversed by refeeding or administration of insulin. Insulin is a 
major metabolic hormone. Like leptin, levels of plasma insulin vary directly with changes in 
adiposity being influenced to a great extent by peripheral insulin sensitivity. The latter is 
related to total body fat stores and fat distribution, with visceral fat being the key 
determinant [12]. Plasma insulin increases at times of positive energy balance and decreases 
at times of negative energy balance. However, unlike leptin, insulin secretion increases 
rapidly after a meal, whereas leptin levels are relatively insensitive to meal ingestion. Both 
leptin and insulin cross the blood-brain barrier, stimulate anorexigenic α-MSH/CART 
neurons and inhibit orexigenic NPY/AgRP neurons, thus activating the catabolic pathways 
and inhibiting the anabolic pathways (Figure 1). When energy stores are low, production of 
leptin from adipose tissue, and thus circulating leptin concentrations fall, leading to 
increased production of hypothalamic neurotransmitters that strongly increase food intake, 
such as NPY, galanin, and AgRP and decreased levels of α-MSH, CART, and neurotensin 
that reduce food intake and increase energy expenditure [8, 13]. 
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CRH, corticotrophin-releasing hormone; MCH, melanin-concentrating hormone, 5-HT, 5-hydroxytryptamine; NE, 
norepinephrine; (- - ) inhibition; ( ) stimulation. 
Figure 1. Schematic action of leptin and insulin on the hypothalamus. 
In addition to leptin and insulin, receptors for ghrelin are also located on arcuate AgRP/NPY 
neurons, which are activated by central ghrelin administration. Furthermore, peripheral 
ghrelin administration activates neurons in the ARC and AgRP and NPY have been 
demonstrated to be requisite mediators of the hyperphagia induced by systemic ghrelin [11]. 
So, meal-generated satiety signals from the GI tract do interact with longer-term adiposity 
signals, such as insulin and leptin in energy balance [8]. 
NPY is one of the most abundant peptides of the hypothalamus and one of the most potent 
orexigenic factors. The majority of neurons expressing NPY in the hypothalamus are found 
within the ARC and most co-express AgRP [14]. Synthesis and release of NPY are both 
regulated by leptin binding to its hypothalamic receptor. NPY links afferents reflecting the 
nutritional status of the organism from endocrine, gastrointestinal, and central and 
peripheral nervous systems to effectors of energy intake and expenditure [15]. NPY 
stimulates appetite inducing hyperphagia, increase of fat depots, decrease of thermogenesis, 
and suppression of sympathetic activity. NPY is known to be involved in other 
physiological functions, such as cardiovascular regulation, affective disorder, memory 
retention, neuroendocrine control. When leptin levels increase after food intake, the latter 
binds to its receptors in the hypothalamus which leads to discontinuation of NPY secretion 
[5, 16]. The decrease of NPY concentration in obesity probably plays a role of a counter-
regulatory factor intended to prevent further weight gain. Thus, NPY becomes one of the 
main regulators of food intake, body weight and energy expenditure. 
Ghrelin is a fast-acting hormone, seemingly playing a role in meal initiation. Secreted 
predominantly from the stomach, ghrelin is the natural ligand for the growth hormone 
secretagogue-receptor (GHS-R) in the pituitary gland, thus fulfilling the criteria of a brain–
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gut peptide [5, 6]. Although the majority of ghrelin is produced peripherally, there are 
ghrelin immunoreactive neurons within the hypothalamus that have terminals on 
hypothalamic NPY/AgRP, POMC and corticotropin releasing hormone (CRH) neurons [17], 
as well as orexin fibres in the LHA [18]. It was found that ghrelin acts to promote appetite in 
two ways—directly, by depolarizing the orexigenic NPY/AgRP neurons, and indirectly, by 
increasing the tonic inhibition exerted by the NPY/AgRP neurons over the anorexigenic 
POMC/CART neurons. Both of these ultimately enhance appetite [4, 17, 18]. The ability of 
ghrelin to increase food intake and body weight is mediated through the stimulation of NPY 
production in the hypothalamic ARC, where it antagonizes the inhibitory effect on NPY 
secretion displayed by leptin and insulin [19]. 
The purpose of this chapter is to provide background information on the relationship 
between the main appetite regulatory peptides NPY and ghrelin, and insulin resistance. The 
role of NPY and ghrelin in food intake and body weight control in humans, and their 
mechanism of action are discussed, focusing on association with glucose metabolism and 
insulin resistance.  
2. Neuropeptide Y (NPY) 
NPY is one of the most abundant peptides of the hypothalamus and one of the most potent 
orexigenic (appetite-increasing) factors [20]. It is a 36-amino acid peptide that was first 
isolated from porcine brain in 1982 [21] (Fugure 2). It is a member of the PP-fold family of 
peptides which consists of NPY, peptide YY (PYY), pancreatic polypeptide (PP) and peptide 
Y (PY) [22]. 
 
Figure 2. Structure of NPY. 
NPY is synthesized by cell bodies in the ARC and transported axonally to the PVN where 
the highest concentrations are found [23]. NPY-expressing neurons are prominent also in the 
DMN and the VMN [24]. All these regions of the brain influence feeding behavior and 
energy balance.  
NPY is also found in circulating blood, where it comes mainly from the adrenal medulla and 
sympathetic nerves, but this peripheral hormone does not cross the blood-brain barrier [25, 
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26]. NPY is present in the pancreas, in both the islet cells and in sympathetic nerve terminals 
[27, 28].  
Regulation of NPY synthesis and release 
The levels of hypothalamic NPY mRNA and NPY release increase with fasting and decrease 
after refeeding [29-31]. When fed with a high-carbohydrate diet; diabetic rats exhibit 
increased gene expression of the NPY in the hypothalamic ARC, and high-fat diet 
suppressed NPY expression [32]. Thus, NPY synthesis as well as its receptorial expression 
are sensitive to changes in the metabolic status and food availability. While starvation and 
food deprivation increase NPY release [30], in obese subjects the activity of NPY neurones is 
down-regulated in the attempt to restrain overeating of palatable food [33]. These facts 
support the existence of a long loop control system in energy metabolism between the brain 
and adipose tissue. Several peripheral factors are involved in the modulation of this system. 
Among them insulin and leptin display an inhibitory effect; glucocorticoids and ghrelin act 
as stimulatory afferent signals [34]. 
It has been reported that leptin is a major inhibitory regulator of the activation by ghrelin of 
the orexigenic network of NPY [35]. Circulating leptin crosses the blood brain barrier and 
binds to the long form of the leptin receptor, Ob-Rb, in the hypothalamus [36]. The Ob-Rb is 
expressed widely within the hypothalamus but particularly in the ARC, VMN, DMN and 
LHA. Several experimental studies demonstrate that systemic administration of leptin 
inhibits NPY gene overexpression through a specific action in the ARC. Cells within the 
ARC express both NPY and leptin receptors, and leptin directly activates anorectic POMC 
neurons and inhibits orexigenic AgRP/NPY neurons [37]. All available data can be 
summarized as follows: when leptin levels increase after food intake, the latter binds to its 
receptors in the hypothalamus which leads to discontinuation of NPY secretion. When 
production of leptin from adipose tissue is reduced, the circulating leptin concentrations fall, 
and this lead to enhanced production of NPY that strongly increase food intake.  
Receptors for ghrelin are also located on arcuate AgRP/NPY neurons, which are activated by 
central ghrelin administration. Ghrelin acts by depolarizing the orexigenic NPY/AgRP 
neurons, and by increasing the tonic inhibition exerted by the NPY/AgRP neurons over the 
anorexigenic POMC/CART neurons [11]. c-Fos expression increases within NPY-
synthesizing neurons in the ARC after peripheral administration of ghrelin [38], and ghrelin 
fails to increase food intake following ablation of the ARC [39]. Studies of knockout mice 
demonstrate that both NPY and AgRP signalling mediate the effect of ghrelin, although 
neither neuropeptide is obligatory [40]. 
Insulin is a major metabolic hormone produced by the pancreas and the first adiposity signal 
to be described. Little or no insulin is produced in the brain itself [41, 42]. Insulin levels are 
dependent on peripheral insulin sensitivity that is related to total body fat stores and fat 
distribution, with visceral fat being a key determinant of insulin sensitivity [12]. Once insulin 
enters the brain, it acts as an anorexigenic signal, decreasing food intake and subsequently 
body weight. It was found that both the NPY and melanocortin systems are important 
downstream targets for the effects of insulin on food intake and body weight. Insulin 
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penetrates the blood–brain barrier via a saturable, receptor-mediated process, at levels which 
are proportional to the circulating insulin [43]. Insulin receptors are widely distributed in the 
brain, with highest concentrations found in the olfactory bulbs and the hypothalamus [44]. 
Within the hypothalamus, there is particularly high expression of insulin receptors in the ARC; 
they are also present in the DMH, PVN, and suprachiasmatic and periventricular regions [45]. 
Hypothalamic NPY is a potential mediator of the regulatory effects of insulin. The increase of 
NPY levels in the PVN and prepro-NPY mRNA in the ARC during fasting are inhibited by 
intracerebroventricular (icv) administration of insulin. Fasting, therefore, increases NPY 
biosynthesis along an ARC-PVN pathway in the hypothalamus via a mechanism dependent 
on low insulin levels [46]. NPY expression is increased in insulin-deficient, streptozocin-
induced diabetic rats and this effect is reversed with insulin therapy [47, 48]. Insulin receptors 
have been found also on POMC neurons in the ARC [49]. Administration of insulin into the 
third ventricle of fasted rats increases POMC mRNA expression and the reduction of food 
intake caused by icv injection of insulin is blocked by a POMC antagonist [49]. Furthermore, 
POMC mRNA is reduced by 80% in rats with untreated diabetes, and this can be attenuated 
by peripheral insulin treatment which partially reduces the hyperglycaemia [50].  
Glucocorticoid hormones play a critical role in energy balance and also appear to mediate at 
least some of their actions through the central NPY axis. They may regulate NPY-induced 
insulin release and NPY signaling within the VMH of the hypothalamus. Glucocorticoid-
receptor immunoreactivity is found within the rat CNS, including the ARC, VMH, and PVN 
[51]. Many of these receptors are expressed at the nucleus of NPY-containing, endocrine-
related neurons and coexist in regions containing high NPY receptor density [52]. In rats, 
excessive corticosterone promotes body fat gain and hyperinsulinemia [53] and also 
increases NPY synthesis and Y1-receptor mRNA expression, at least within the ARC ([54, 
55]. Conversely, removal of glucocorticoids by adrenalectomy reduces hyperphagia and 
body weight of obese (fa/fa) rats [56], abolishes obesity induced by VMH lesions [57], and 
prevents obesity induced by chronic central NPY infusion in normal rats [58]. However, it 
has been reported that adrenalectomy does not alter NPY-1 (Y1)-receptor mRNA expression 
in the ARC [54]. Chronic icv infusion of NPY induces hyperphagia, hyperinsulinemia, and 
insulin resistance in rats, and these effects are blocked by previous adrenalectomy [59]. 
Wisialowski et al. [60] have demonstrated that adrenalectomy also abolishes the insulin 
release caused by an acute icv injection of NPY and this is associated with significant 
reduction in Y1- and Y5-receptor mRNA expression specifically within the VMH. These 
experiments imply that glucocorticoids are necessary for icv NPY to stimulate insulin 
release and suggest that the latter manifest this regulatory role through alterations in Y1- 
and Y5-receptor expression in the VMH [60]. Taken together, all these observations indicate 
that glucocorticoids have a regulatory role in long-term central NPY signaling. 
As concerns plasma NPY, its concentrations rise in response to muscular exercise [61] and in 
disorders such as pheochromocytoma and renal failure [62]. 
Mechanisms of action of NPY – NPY receptors 
PP-fold family of peptides bind to seven transmembrane-domain G-protein-coupled 
receptors [63]. Heterogeneity among NPY (and PYY) receptors was first proposed on the 
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basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert 
three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional 
potentiating effect on norepinephrine (NE)-evoked vasoconstriction; and 3) a prejunctional 
suppression of stimulated NE release. The two latter phenomena are probably reciprocal, 
since NE affect NPY mechanisms similarly [64]. Six different NPY receptors have been 
identified ([65], of which five have been cloned and characterized. Y1–Y5 receptors have 
been demonstrated in rat brain, but Y6, identified in mice, is absent in rats and inactive in 
primates [66]. The Y1, Y2, Y4 and Y5 receptors, cloned in the hypothalamus, have all been 
postulated to mediate the orexigenic effects of NPY. Biological redundancies are likely to 
exist between Y1 and Y5 receptor signaling [67].  
NPY initiates appetite drive directly through its receptors, particularly the Y1-5 (NPY5-R), 
and by the simultaneous inhibition of anorexigenic melanocortin signalling in the ARC [68]. 
NPY5-R is thought to be the main receptor involved in NPY-induced food intake since a 
reduction in food intake after an icv injection of antisense oligonucleotides directed against 
NPY5-R is demonstrated in rats [69].  
Although the large number of Y receptors has made it difficult to delineate their individual 
contributions, recent studies analyzing  NPY and Y receptor-overexpressing, knockout, and 
conditional-knockout mouse models have started to unravel some of the complexity.  To 
elucidate the role of NPY1-R in food intake, energy expenditure, and other possible 
functions, Kushi et al. [70] have generated  NPY1-R-deficient mice (Y1-R-/-) by gene 
targeting. Contrary to their hypothesis that the lack of NPY signaling via Y1-R would result 
in impaired feeding and weight loss, Y1-R-/- mice showed a moderate obesity and mild 
hyperinsulinemia without hyperphagia. The authors suggest either that the Y1-R in the 
hypothalamus is not a key molecule in the leptin/NPY pathway, which controls feeding 
behavior, or that its deficiency is compensated by other receptors, such as NPY5-R. Probably 
the mild obesity found in Y1-R-/- mice was caused by the impaired control of insulin 
secretion and/or low energy expenditure [70]. This model could be useful for studying the 
mechanism of mild obesity and abnormal insulin metabolism in noninsulin-dependent 
diabetes mellitus. 
In order to investigate the role of different Y receptors in the NPY-induced obesity 
syndrome, Lin et al. [71] used recombinant adeno-associated viral vector to overexpress 
NPY in mice deficient of selective single or multiple Y receptors (including Y1, Y2, and Y4). 
Results from this study demonstrated that long-term hypothalamic overexpression of NPY 
lead to marked hyperphagia, hypogonadism, body weight gain, enhanced adipose tissue 
accumulation, hyperinsulinemia, and other hormonal changes characteristic of an obesity 
syndrome. NPY-induced hyperphagia, hypogonadism, and obesity syndrome persisted in 
all genotypes studied (Y1−/−, Y2−/−, Y2Y4−/−, and Y1Y2Y4−/− mice). However, triple deletion of 
Y1, Y2, and Y4 receptors prevented NPY-induced hyperinsulinemia. These findings suggest 
that Y1, Y2, and Y4 receptors under this condition are not crucially involved in NPY’s 
hyperphagic, hypogonadal, and obesogenic effects, but they are responsible for the central 
regulation of circulating insulin levels by NPY [71].  
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A lot of investigators’ data point that NPY5-R mediates the feeding response to exogenous 
and endogenous NPY. It may be involved in energy balance and is, therefore, a 
susceptibility candidate gene for obesity and related disorders such as the metabolic 
syndrome and type 2 diabetes mellitus. It is hypothesized that the feeding effect of NPY 
may indeed be mediated by a combination of receptors rather than a single one. Also, 
increasing evidence points to the existence of other as yet unidentified Y receptors, which 
may mediate NPY’s orexigenic actions, and it remains possible that, under certain 
physiological conditions, NPY may bind and activate receptors for which it normally has no 
or only low affinities. 
Analogs of NPY with high selectivity for the Y1 and Y5 receptor subtypes strongly stimulate 
food intake in rodents, and icv administration of specific Y5 receptor agonists increases food 
intake and body weight in mice [72]. A clinical study examining a therapeutic intervention 
based on the NPY system has been performed by Erundu et al. [73]. The authors tested the 
hypothesis that blockade of the NPY5-R will lead to weight loss in humans using MK-0557, 
a potent, highly selective, orally active NPY5-R antagonist. MK-0557 has no significant 
binding to the human NPY1-R, NPY2-R, NPY4-R, or mouse NPY6-R at concentrations of 10 
μM. These data indicate a >7500-fold selectivity for the NPY5-R relative to the other NPY 
receptor subtypes. MK-0557 was administered to 547 obese subjects, who showed 
statistically significant weight loss at 12 weeks compared to subjects treated with placebo 
[73]. These observations clearly indicate that antagonizing the NPY5-R induces weight loss 
in humans. After that a long-term trial over 52 weeks was performed in 1661 subjects (832 
completed). There was a a mean weight loss of 3.4 kg in those who completed the trial, 
which was significantly greater than the weight loss seen in the placebo-treated group. 
Significantly more subjects lost ≥5% and ≥10% of initial body weight with the NPY5-R 
antagonist than did so on placebo. The authors conclude, however, that the magnitude of 
the weight loss observed was not clinically significant, and this conclusion is supported by 
the observation that there were no significant improvements in secondary endpoints such as 
glucose and lipid levels and blood pressure measurements [73]. While several potential new 
obesity therapies that act through the CNS pathways or peripheral adiposity signals are in 
early-phase clinical trials, the above study serves to point out that manipulation of the 
homeostatic mechanisms involving hypothalamic/brainstem pathways for a clinically 
significant outcome in obese patients remains a major challenge [74]. 
Link between NPY, obesity and insulin resistance 
NPY is a powerful stimulant of food intake. Numerous studies in rodent models have 
demonstrated that administration of NPY into the PVN stimulates feeding [75, 76] and that 
repeated injections of NPY result in persistent feeding and the development of obesity by 
promoting fat accumulation [77, 78]. Central administration of NPY was found to reduce 
energy expenditure, resulting in reduced brown fat thermogenesis [79], suppression of 
sympathetic nerve activity [80] and inhibition of the thyroid axis [81]. There are some data 
that NPY activates hypothalamic-pituitary-adrenal axis (HPA) [82], that is implicated in the 
regulation of metabolism and energy balance. An acute injection of NPY into the PVN 
produces increases in circulating ACTH and corticosterone in both conscious and 
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anesthetized rats [83]. ARC NPY neurons project to the ipsilateral PVN [84], and repeated 
icv injection of NPY into the PVN in normal rats causes hyperphagia, an increase in basal 
plasma insulin level and morning cortisol level, independent of increased food intake, 
increased metabolic activity of white adipose tissue and muscle insulin resistance, and 
results in obesity [85, 86]. Several of these metabolic effects are still present when increased 
food intake is prevented by food restriction [85]. It was shown that Y5 receptor subtype is 
involved in the activation of HPA axis mediated by NPY [82].  
Interestingly, injection of NPY directly into the VMH significantly increases food intake [75], 
and NPY-induced feeding is enhanced in VMH-lesioned rats [87]. Lesions of the VMH in 
rodents also cause multiple changes in metabolic status, including hyperphagia, 
hyperglycemia, and hyperinsulinaemia [88]. Enhanced NPY expression in the VMH is 
associated with obesity [89]. Furthermore, NPY has been shown to directly inhibit over one 
fifth of spontaneously active rat VMH neurons, and this inhibition is potentiated by 
overfeeding [90]. Therefore, the mechanism by which acute icv NPY stimulates insulin 
release in the absence of feeding may be by inhibiting the spontaneous activity of the VMH 
through Y1 and Y5 receptors. A reduction of these receptors with adrenalectomy would 
then reduce the ability of NPY to inhibit VMH neurons. These data suggest the VMH may 
also be a site of action for NPY in the development of obesity; however, the mechanisms by 
which NPY is involved in each aspect of central energy regulation remain to be defined.  
Some investigators found that acute icv NPY administration had no affect on plasma 
glucose levels, indicating that NPY-induced insulin release is not simply a secondary 
response to changes in peripheral glucose [60, 91]. The decreased basal insulin levels and 
lack of insulin release in response to NPY injection in adrenalectomized rats with 
downregulation of Y1-and Y5-receptor mRNA in the VMH, demonstrated in the study of 
Wisialowski et al. [60], highlights the role for Y1-and Y5-receptors in the etiology of NPY-
induced hyperinsulinemia, insulin resistance, and obesity.  
Van den Hoek et al. [92] found that icv administration of NPY in the third ventricule in rats 
acutely hampers the capacity of insulin to suppress endogenous glucose production via 
activation of sympathetic nerves innervating the liver The authors discusssed a possible 
explanation for the role of NPY in sympathetic overdrive and hepatic insulin resistance that 
are typical for obese subjects with the metabolic syndrome [92]. In a study of Singhal et al. 
[93] the ability of resistin to increase hepatic insulin resistance and modulate the levels of 
various mediators in the liver was abolished in mice lacking NPY as well as in mice 
pretreated with icv NPY Y1 receptor antagonist. The authors established a crucial link 
between NPY and resistin’s ability to regulate hepatic insulin resistance possibly via 
induction of SOCS3 (suppressor of cytokine signaling-3), tumor necrosis factor (TNF)-α and 
interleukin 6 (IL6). Additionally, NPY is critical to mediating the decrease in STAT3 (signal 
transducer-activated transcript-3) phosphorylation by central resistin [93]. 
It was found that the obesity syndrome, induced by injection of NPY into the CNS of rats, 
closely resembles the phenotype of either leptin deficient ob/ob mice, or leptin resistant db/db 
mice [58, 85]. In these animals, genetic alterations of the satiety effect of leptin within the 
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hypothalamus result in an overexpression of NPY leading to a complex syndrome including 
hyperphagia, increased fat storage and obesity. The experimental studies in ob/ob mice 
demonstrate that systemic administration of leptin inhibits NPY gene overexpression 
through a specific action in the ARC and exerts a hypoglycemic action that is partly 
independent of its weight-reducing effects. It must be pointed that both effects occur before 
reversal of the obesity syndrome. Defective leptin signaling due to either leptin deficiency 
(in ob/ob mice) or leptin resistance (in db/db mice) therefore leads directly to hyperglycemia 
and the overexpression of hypothalamic NPY, that is implicated in the pathogenesis of the 
obesity syndrome [94]. Moreover, the obesity syndrome produced by icv administration of 
NPY is characterised by increased expression of the ob gene in adipose tissue [58]. On the 
other hand leptin, the ob gene product, has been shown to inhibit NPY synthesis and release 
from hypothalamic nuclei in ob/ob mice. Correction of the obese state induced by genetic 
leptin deficiency reduces elevated levels of both blood glucose and hypothalamic NPY 
mRNA [95].  
Although NPY seems to be an important orexigenic signal, NPY-null mice have normal 
body weight and adiposity [96, 97]. This absence of an obese phenotype may be due to the 
presence of compensatory mechanisms or alternative orexigenic pathways, such as those 
which signal via AgRP [98]. It is possible that there is evolutionary redundancy in orexigenic 
signalling in order to avert starvation. This redundancy may also contribute to the difficulty 
elucidating the receptor subtype that mediates NPY-induced feeding [99].  
In searching the role of NPY in human obesity and metabolic disorders, polymorphisms in 
the NPY5-R gene have been studied by other authors in several populations. Thus, NPY5-R 
gene was sequenced by Jenkinson et al. [100], and several single nucleotide polymorphisms 
(SNPs) were genotyped in the Pima Indians with three novel SNPs being identified, which 
were described as polymorphism 1, 2, and 3 (P1, P2, and P3). All three SNPs are in non-
coding regions. There were genotype differences in lean and obese Pima Indians for P2 and 
for a 3 SNP haplotype [100]. A silent single nucleotide polymorphism within the NPY5-R 
coding sequence showed no evidence of association with BMI in children and adolescents 
[101]. In contrast, a novel polymorphism in the intervening segment between exons of the 
genes encoding NPY1-R and NPY5-R was associated with reduced serum triglyceride (TG) 
levels and HDL-cholesterol in a severely obese cohort [102] that should be considered as a 
protective lipid profile. Roche et al. [103] investigated the potential implication of NPY, 
NPY-Y1 and -Y5 subtype receptors [rNPY-Y1/-Y5] in the development of human obesity. 
Two complementary genetic approaches were used: 1) linkage analyses between obesity and 
polymorphic markers located nearby NPY and rNPY-Y1/-Y5 genes in 93 French Caucasian 
morbidly obese families; 2) single strand conformation polymorphism (SSCP) scanning of 
the coding region of the NPY and rNPYY1 genes performed in 50 unrelated obese patients 
ascertained. No evidence of linkage between morbid obesity or obesityrelated quantitative 
traits and NPY and rNPY-Y1/Y5 regions was found in this population. Moreover, SSCP 
scanning revealed no mutation in the coding region of NPY and rNPY-Y1 genes among 
obese subjects. The authors suggest that NPY and NPY-Y1/ Y5 receptors are unlikely to be 
implicated in the development of human morbid obesity, at least in the French Caucasian 
population [103]. 
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In addition to the above data, genetic association of NPY receptor Y5 (NPY5R) SNPs with 
metabolic syndrome was studied in 439 Mexican American individuals by Coletta et al. 
[104]. Minor alleles for five of nine genetic variants (rs11100493, rs12501691, P1, rs11100494, 
rs12512687) of the NPY5-R SNPs were found to be significantly associated with both 
increased plasma TG levels and decreased high-density lipoprotein (HDL) concentrations 
[104]. In addition, the minor allele for SNP P2 was significantly associated with a decreased 
homeostasis model assessment of -cell function (HOMA-%). Linkage disequilibrium 
between SNPs pairs indicated one haplotype block of five SNPs (rs11100493), and low HDL-
cholesterol are highly associated with insulin resistance states, such as type 2 diabetes 
mellitus, obesity, and the metabolic syndrome. So, these results provide evidence for 
association of SNPs in the NPY5R gene with atherogenic dyslipidemia in insulin resistance. 
In the course of identification of genes implicated in the development of human obesity, 
further genome-wide searches could be successful for identifying multiple predisposing 
loci. 
It has become apparent, that upon vigorous electrical stimulation or intense stressors motor 
neurons on the sympathetic nerve system (SNS) may secrete NPY as well as NE [105]. 
Acting through NPY receptors on vascular and adipose tissue, secreted NPY may play an 
important role in the pathophysiology of obesity and metabolic syndrome. Thus, Kuo et al. 
[105] demonstrated that stress exaggerated diet-induced obesity through a peripheral 
mechanism in the abdominal white adipose tissue that is mediated by NPY. The authors 
found that stressors such as exposure to cold or aggression lead to NPY release from SNS, 
which in turn upregulates NPY and its Y2 receptors (NPY2-R) in a glucocorticoid-dependent 
manner in the abdominal fat. This positive feedback response by NPY lead to abdominal fat 
enhancement. Release of NPY and activation of NPY2-R stimulated fat angiogenesis, 
macrophage infiltration, and the proliferation and differentiation of new adipocytes, 
resulting in abdominal obesity and a metabolic syndrome-like condition. NPY, like stress, 
stimulated fat growth, whereas pharmacological inhibition or fat-targeted knockdown of 
NPY2R is anti-angiogenic and anti-adipogenic. Thus, manipulations of NPY2-R activity 
within fat tissue offer new ways to remodel fat and treat obesity and metabolic syndrome 
[105]. 
NPY may be an important intra-islet paracrine hormone [38]. When produced by pancreatic 
islets, its expression is dependent on the prevailing endocrine environment. Islet NPY 
appears to constrain insulin release under a variety of conditions. Whether peripheral NPY 
has a hormone-like action and directly influences glucose metabolism and/or insulin 
secretion in vivo is under investigation. It this context NPY, at high concentrations, may 
contribute to the modulation of insulin secretion in vitro. NPY nerve fibers occur in the 
mouse pancreas and that most of these NPY nerve fibers are nonadrenergic. Furthermore, in 
the mouse, NPY enhances basal plasma insulin levels at high dose levels under in vivo 
conditions. At lower dose levels it inhibits glucose-induced, but not cholinergically induced 
insulin secretion [106]. It has also been reported that NPY may reduce plasma glucose 
concentrations during exercise by inhibiting glycogen breakdown in the splanchnic 
compartment [107, 108]. Moreover, the potential relation between circulating NPY and the 
pathophysiological consequences of obesity need further investigation.  
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Vettor et al. [109] found that peripheral NPY infusion in normal rats increased the overall 
rate of glucose disposal by increasing insulin responsiveness in skeletal muscle. Plasma 
leptin was significantly increased by hyperinsulinaemia, but was not affected by NPY 
infusion. Both the early and late phase of the insulin response to hyperglycaemia were 
significantly reduced by NPY. Based on their data for an increased glycolytic flux combined 
with a blunted increase in lactate, the authors suggested that NPY may raise insulin 
mediated glucose disposal by increasing its utilisation through the oxidative pathways. 
Intravenous NPY did not influence glucose metabolism in adipose tissue and leptin release 
[109].  
The above data indicate that NPY has different effects on insulin secretion when 
administered acutely via intracerebroventricular or intravenous routes. Thus, peripheral 
NPY plays a clear inhibitory role in glucose-induced insulin secretion. It is also possible that 
the duration of treatment, and not just the route of administration, may be a relevant factor. 
Several appetite-regulating genes (MCH, CRH, NPY, cholecystokinin, etc.) as well as their 
corresponding receptors, are expressed in the adipose tissue. The coexistance of locally 
produced NPY and NPYR-2 suggests a NPY autocrine/paracrine system of regulation of 
adipocyte function. Kos et al. reported that NPY is not only expressed but also secreted by 
human adipose tissue and insulin increases NPY secretion [110]. Direct effects of NPY on 
adipocyte function are also described. Thus, NPY was as potent as insulin in increasing both 
leptin and resistin secretion from pre-adipocytes from visceral fat in vitro [105]. Treatment 
of human subcutaneous adipocytes with recombinant human NPY downregulates leptin 
receptor [110], exerts an anti-lipopytic effect probably mediated by adenylate cyclase 
inhibition [111], and promotes the proliferation of pre-adipocytes [105, 112]. Probably, the 
enhanced local expression of NPY within visceral adipose tissue may contribute to the 
molecular mechanisms underlying increased visceral adiposity. The anti-lipolytic action on 
NPY can promote an increase in adipocyte size in hyperinsulinaemic conditions, such as 
abdominal obesity and metabolic syndrome.  
As compared to the numerous experimental and genetic studies, the clinical studies on 
circulatory NPY in obesity are not so many. It is interesting that significant alteration of NPY 
circulatory levels is not found in adults after weight reduction [113] as well as in adolescents 
[114] besides the progressive decrease of leptin levels. Probably, the leptin control on 
hypothalamic production of NPY cannot be estimated by the levels of the latter in 
peripheral circulation. 
In one of our recent studies on different morphological types of obesity [115], NPY levels in 
obese women were lower than those of the normal weight controls, the differences being 
significant when comparing the obese group as a whole and the subgroup with android 
obesity only (Table 1). There was a reverse correlation between NPY and body weight, and 
percentage body fat. In analogy with the comparisons regarding NPY, leptin levels did not 
differ significantly between the two groups of obese women. Our data are in accordance 
with the data of Zahorska-Markiewicz et al. in obese women and in women with normal 
weight [113]. Notwithstanding the absence of statistically significant differences in leptin 
 
Appetite Regulatory Peptides and Insulin Resistance 101 
and NPY levels between our obese patients, we observed that at relatively highest leptin 
levels NPY had relatively lowest levels, and vice versa. This was supported by the 
ascertained negative correlation between the two hormones. In the control group, 
significantly lower leptin levels were associated with significantly higher NPY levels as 
compared to the obese group. We can suggest that the decrease of NPY concentration in 
obesity may play a role of a counter-regulatory factor intended to prevent further weight 
gain. In this and previous study of ours [116] we did not find significant differences in 
circulatory levels of resistin and TNF between lean women and women with both gynoid 
and android obesity. The latter were insulin-resistant with significantly higher basal 
insulinaemia and HOMA-index, respectively (Table 1).  
 
Hormones 
Leptin
(ng/ml) 
Resistin
(ng/ml) 
TNFα
(pg/ml) 
NPY
(ng/ml) 
Insulin
(μIU/ml) 
HOMA 
index 
Android obesity
(n=32) 
21.28±11.14* 2.350.59 15.756.79 4.591.13* 20.138.17*# 4.341.68*# 
Gynoid obesity
(n=27) 
17.149.05 2.240.76 18.186.07 5.211.19 10.475.24 2.181.34 
Controls 
(n=24) 
10.025.98 2.091.19 19.179.08 5.991.18 8.033.22 1.690.98 
(All data are expressed as meanSD.* - significant difference as compared to the control group; # - significant difference 
as compared to the group with gynoid obesity) 
Table 1. Hormonal parameters and HOMA-index in the women with obesity and normal weight 
women [115].  
The NPY levels were found similar in a group of patients with gestational diabetes mellitus 
and in pregnant women with normal glucose tolerance in a study of Ilhan et al [117]. 
Notably, the NPY concentration correlated positively with insulin levels in patients with 
type 2 diabetes mellitus [117]. These data suggest a potential involvement of circulating 
NPY in diabetes pathology that needs further purposeful studies.  
NPY and reproductive function 
Having in mind the fact, that NPY secretion is increased in response to metabolic challenges 
that inhibit luteinizing hormone releasing hormone (LHRH) secretion (e.g., fasting) and 
decreased by treatments that restore the metabolic deficit and reinstate reproductive 
function (e.g., re-feeding) [20], several studies have focused on the role of NPY in 
reproductive processes.  
A modulating action of NPY on the gonadotropic and somatotropic systems in experimental 
animals has been reported. NPY affects luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) release from anterior pituitary cells in vitro and enhances LHRH-induced 
LH secretion [118]. In female rats NPY decreased LH release in pituitary cell culture in vitro 
[119]. Barb et al. [120] conducted 2 experiments in ovariectomized prepubertal gilts to test 
the hypothesis that NPY stimulates appetite and modulates LH and growth hormone (GH) 
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secretion, and that leptin modifies such acute effects of NPY on feeding behavior and LH 
and GH secretion. In the first one, gilts received icv injections of NPY. In the second one gilts 
received icv injections of leptin, NPY or NPY + leptin, and feed intake was measured. The 
authors found that NPY suppressed LH secretion and the 100 μg dose stimulated GH 
secretion. NPY reversed the inhibitory effect of leptin on feed intake and suppressed LH 
secretion, but serum GH concentrations were unaffected [120]. In another experiment in 
prepubertal gilts, Barb et al. [121] demonstrated that NPY did not alter basal LH secretion 
nor 10(-8) M LHRH-induced increase in LH secretion but 10(-9) M LHRH-stimulated LH 
secretion was reduced by NPY and was not different from control or LHRH alone. At the 
same time NPY increased basal GH secretion and enhanced the GH response to growth 
hormone releasing factor (GRF) at the level of the pituitary gland [121]. These data support 
the modulating role of NPY on GH and LH secretion. Experimental evidence in rodents and 
monkeys suggests that NPY preferentially exerts inhibitory effects on LHRH-LH secretion 
when estrogen levels are low [122, 123]. In primates, the role of NPY as a regulator of 
gonadotropin secretion is complicated by the observation that age may influence the effects 
of NPY (inhibitory or stimulatory), as does the site of exogenous NPY administration [124, 
125]. An important physiological role for NPY as a modulator of neuroendocrine activity 
which culminates in the preovulatory surge of LH is discussed [118] 
All above mentioned and many similar results support the hypothesis that NPY modulates 
feed intake, and LH and GH secretion and may serve as a neural link between metabolic 
state and the reproductive, as well as the growth axis. 
Clinical evidence suggests that NPY exerts primarily an inhibitory effect on the 
hypothalamic-pituitary-ovarian (HPO) axis in humans. Thus, a role for NPY in 
hypothalamic amenorrhea is inferred from the observation that NPY levels in the 
cerebrospinal fluid and serum are elevated in underweight amenorrheic women, and are 
returned to normal after long-term weight restoration in women who resumed normal 
menstrual cycling [126-128]. Starvation-induced alterations of neuropeptide activity 
probably contribute to neuroendocrine dysfunctions in anorexia nervosa. Kaye et al. [126] 
made the conclusion, that in girls with anorexia nervosa a disturbance of CNS corticotropin 
releasing hormone (CRH) activity is likely to be responsible for hypercortisolemia, while a 
disturbance of CNS NPY may contribute to amenorrhea [126]. In addition, disturbances of 
these neuropeptides could contribute to other symptoms such as increased physical activity, 
hypotension, reduced sexual interest, depression, and pathological feeding behavior [129]. 
Similarly, a role for NPY in the initiation of puberty is suggested by the observation that 
concentrations of NPY in girls with delayed puberty are higher than in girls matched for 
weight and body composition who exhibited normal pubertal development [130].  Higher 
concentrations of NPY in girls with constitutional delay of puberty (CDP) may be 
responsible for the disorder and reduced levels of IGF-I. Correlation of NPY with % body fat 
suggests an involvement of this neuropeptide in the process of fat accumulation associated 
with CDP [130]. 
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Of great interest is to focus on the role of NPY in one of the most common endocrine-
metabolic diseases, affecting up to 10% of women of reproductive age, the polycystic ovary 
syndrome (PCOS) [131, 132]. It is widely accepted that PCOS is a prototype of a sex specific 
metabolic syndrome [132-134]. Obesity is present in 30–70% of affected women depending 
on the setting of the study and the ethnical background of the subjects, and it is 
characterized by central distribution of fat [133, 135, 136]. In women with PCOS, 
hyperinsulinemia, dyslipidemia, and/or hypertension are highly dependent on obesity, 
which worsens all of the clinical manifestations of PCOS [133, 136-138]. At present there is 
an increasing body of evidence of high levels of atherogenic adipocytokines and low levels 
of adiponectin in women with PCOS that change according to variations of fat mass [139]. 
Endocrine function of the adipocytes is regulated mainly by nutritional status, and both 
these factors are complexly interweaved in the energy storing mechanism in the adipose 
tissue [140]. It is still not fully elucidated if there are consistent differences in the levels or in 
the effects of appetite-regulating hormones as is NPY in PCOS.  
Manneras et al. [141] demonstrated an enhanced mesenteric (visceral) adipose tissue 
expression of NPY in a rat model of PCOS in comparison with normal rats. Exercise reduced 
adiposity and adipose NPY expression and additionally normalized ovarian cyclicity [141]. 
Women with PCOS may exhibit altered leptin sensitivity of the hypothalamic NPY neurons 
to leptin inhibition, and higher plasma NPY levels have been observed in women with 
PCOS compared to nonPCOS controls; this may perturb LHRH secretion [142]. Thus, 
Baranowska et al. [143] found elevated NPY levels in both lean and overweight women with 
anovulatory PCOS. The increase in NPY in their study was independent of the increase in 
BMI. In obese women with PCOS, plasma leptin was increased compared to lean women 
[143]. Bidzińńska-Speichert et al. [144] also found higher leptin and NPY levels and lower 
galanin levels in PCOS women as compared to healthy controls [144]. These data are in 
conformity with observations from our recent on-going study where we found significantly 
higher NPY and leptin levels in obese insulin-resistant PCOS women as compared to 
nonPCOS weight matched women [Orbetzova, unpublished data]. It can be suggested that 
the feedback system in the interaction between leptin and NPY is disturbed in PCOS.  
In contrast, Romualdi et al. [145] demonstrated that in basal conditions, obese PCOS women 
exhibited lower NPY levels than obese controls. Ghrelin injection markedly increased NPY 
in controls, whereas PCOS women showed a deeply blunted NPY response to the stimulus. 
Metformin treatment induced a significant decrease in insulin levels and the concomitant 
recovery of NPY secretory capacity in response to ghrelin in PCOS women. Leptin levels, 
which were similar in the two groups, were not modified by ghrelin injection; metformin 
did not affect this pattern. The authors conclude that hyperinsulinaemia seems to play a 
pivotal role in the alteration of NPY response to ghrelin in obese PCOS women. This 
derangement could be implicated in the pathophysiology of obesity in these patients [145]. 
The limitations of this very interesting study on the ghrelin–NPY relationship in PCOS is the 
small number of patients (seven obese, hyperinsulinaemic subjects with PCOS and seven 
obese control women) and the data need further purposeful investigation. 
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Interventions that influence reproductive and metabolic function in PCOS may also affect 
levels of the adipose tissue hormones and regulators of appetite, such as NPY. It has been 
postulated that some of the effects of insulin-sensitizing agents in PCOS may be mediated 
through changes in adipocytokines levels. Some authors demonstrated that treatment of 
women with PCOS with insulin-sensitising agents induces a reduction in serum leptin levels 
[146-149]. In this context our recent data from a study comprising of 2 groups of overweight 
insulin-resistant PCOS women [150] showed that a 3-month treatment with metformin 
(Group 1) and rosiglitazone (Group 2), added to an oral hormone contraceptive (OHC) (a 
standard combination of ethynil oestradiol 35 g plus cyproterone acetate 2 mg) resulted in 
decrease of atherogenic adipocytokines (leptin, resistin, and TNFα) (Table 2) that may have 
beneficial effects in the future prevention of atherosclerosis and cardiovascular diseases in 
this risk cohort of young women. But the serum concentrations of NPY also decreased that 
is in support of some our previous [151] and other authors [143, 144] data for impaired NPY-
leptin link in PCOS. The change of NPY and adipocytokines was associated with weight loss 
only in the metformin group that is an expected effect of the drug and in conformity with 
other studies [150].  
 
Groups 
 
Parameters 
Group 1 (n=32) 
Metformin + OHC 
Group 2 (n= 34) 
Rosiglitazone +OHC 
0 months 3 months 0 months 3 months 
Leptin (ng/ml) 13.173.42 6.401.40** 15.544.49 7.171.59** 
Resistin (ng/ml) 2.190.67 1.630.45** 2.610.79 1.680.41** 
TNF (pg/ml) 12.525.78 8.473.09*** 13.454.30 9.604.16**** 
NPY (ng/ml) 4.511.18 3.640.46* 4.541.47 3.211.25**** 
Weight (kg) 78.2420.14 75.5018.66** 82.4116.17 82.2315.80 
BMI (kg/m2) 28.454.38 27.453.73** 29.274.24 29.224.27 
Waist (cm) 88.697.72 86.635.92* 88.978.05 88.247.63 
Fats (%) 35.5610.10 33.988.77 35.5512.40 34.7213.09 
Fats (kg) 29.7715.20 27.2313.39* 32.3017.86 31.3317.94 
* - p<0.05 – vs basal; ** - p<0.01 – vs basal; *** - p=0.001 – vs basal; ****- p<0.001 – vs basal 
Table 2. NPY, adipose tissue hormones, and some clinical characteristics of the groups before and after 
treatment [150] 
Having in mind that the decrease in NPY and adipocytokines was not in parallel with 
changes in body weight and composition in the rosiglitazone group and was associated with 
only slignt and non significant influence on hyperinsulinaemia, resp. insulin resistance, 
additional direct adipose tissue and/or disease specific effects of the treatment may come 
into consideration that needs further elucidation. 
3. Ghrelin  
Ghrelin was discovered by Kojima et al. [152] in rat stomach extracts in 1999. This peptide 
has been identified in many species, including mammals, avians, amphibians, reptiles, and 
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fish [153-159] and the sequence of first seven amino acids of the N-terminal region of ghrelin 
are highly conserved between species [160]. 
Ghrelin is an orexigenic factor released primarily from the oxyntic cells of the stomach, but 
also from duodenum, ileum, caecum and colon [161, 162]. Gastric ghrelin cells had been 
classified as X/A-like cells by their round, compact, electron-dense secretory granules that 
distinguish them electron-microscopically from other previously characterized gastric 
endocrine cell types before the discovery of ghrelin [161, 163]. Ghrelin has also been 
detected in many other organs, such as the bowel, pancreas, kidney, placenta, lymphatic 
tissue, gonads, thyroid, adrenal, lung, pituitary and hypothalamus, and in different human 
neoplastic tissues and related cancer cell lines, such as gastric and intestinal carcinoids, 
lymphomas and thyroid, breast, liver, lung and prostate carcinomas. Levels of ghrelin 
expression in these normal and tumoral tissues or cell lines are lower than in the 
stomach, and although the potential physiological role of ghrelin as an autocrine/paracrine 
factor in these tissues is still under investigation [164].  
In mice, rats and humans, ghrelin is an acyl-peptide consisting of 28 amino acids, sharing a 
36% structural resemblance to motilin [165]. A hydroxyl group of serine at position 3 of the 
ghrelin molecule is esterified with an octanoic acid. The esterification increases the 
hydrophobicity of the ghrelin molecule, and is essential for most of its biological activities 
[152,166-168]. An enzyme that catalyses the acyl-modification of ghrelin was discovered in 
2008 by Yang et al. [169], was renamed ghrelin O-acyltransferase (GOAT). In vivo studies 
showed that GOAT gene disruption in mouse models completely abolished ghrelin 
acylation [170, 171]. GOAT inhibition leading to weight reduction and beneficial metabolic 
effects [172] is therefore a useful target for future development of therapeutic compounds 
for obesity and metabolic syndrome. 
Ghrelin receptor 
Ghrelin was discovered via its growth hormone releasing effect as an endogenous agonist of 
the GHS-R, that is still the only receptor so far described [152, 173, 174]. The GHS-R was first 
identified in 1996 as a seven transmembrane domain peptide totaling 366 amino acids. It is a 
G protein-coupled receptor (GPCR) that is linked to both Gq and Gs signaling pathways. It 
generates intracellular signaling through its Gα11 subunit, although the specific intracellular 
pathways elicited by this receptor are dependent on the tissue type in which it is expressed 
[175].  
There are two splice variants - GHS-R type 1a that is the receptor to which ghrelin binds and 
through which it exerts its stimulatory effects on growth hormone release [152, 161, 176, 
177], and GHS-R type 1b, which is a COOH-terminal truncated form of the type 1a receptor, 
and is physiologically inactive [178]. Ghrelin administration does not increase food intake in 
mice lacking GHS-R type 1a, suggesting that the orexigenic effects may be mediated by the 
above receptor; however, these mice have normal appetite and body composition [173, 179]. 
Ghrelin exists as two different molecular forms in both gastric ghrelin-producing cells and 
circulation: 1) acylated ghrelin (with the n-octanoic acid at the serine-3 position), which is 
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essential for activation of GHS-R1a and modulation of neuroendocrine and orexigenic 
effects; and 2) nonacylated ghrelin (des-acyl ghrelin), which is the most abundant form in 
the stomach and circulation but is unable to activate GHS-R1a, and to exhibit further GH-
releasing activity [180] (Figure 3). Nonetheless, food intake is induced by des-acyl ghrelin, 
administered by icv injection, to the same extent as ghrelin [181]. Nonacylated ghrelin exerts 
some cardiovascular and antiproliferative actions. Because the genome database does not 
contain another GPCR that resembles GHS-R, probably des-acyl ghrelin acts by binding 
different GHS-R subtypes or as yet unidentified receptor families  [178, 182]. 
 
Figure 3. Structure of nonacylated and acylated ghrelin 
GHS-R1a is widely distributed in the body with high expression levels in the hypothalamus 
and in all three components of the dorsal vagal complex, including the area postrema, the 
nucleus of the solitary tract (NTS), the dorsal motor nucleus of the vagus and 
parasympathetic preganglionic neurons [183]. Low expression is detected in other brain 
areas and in numerous other tissues including the myocardium, stomach, small intestine, 
pancreas, colon, adipose tissue, liver, kidney, lung, placenta and peripheral T-cells [152, 161, 
182, 184-187].  
The ghrelin receptor is well conserved across all vertebrate species examined, including a 
number of mammals, bird and fish. This strict conservation suggests that ghrelin and its 
receptor serve essential physiological functions [188]. Some studies have also described 
ghrelin analogues which show dissociation between the feeding effects and stimulation of 
GH, suggesting that GHS-R type 1a may not be the only receptor mediating the effects of 
ghrelin on food intake [189]. 
The gene encoding ghrelin also encodes another peptide, called obestatin. The administration 
of obestatin reduces food intake and weight gain in rats via activation of GPR3, an orphan 
G-protein coupled receptor [190, 191]. Therefore, one gene produces two products with 
opposing metabolic effects, which are exercised through different receptors [192]. 
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Ghrelin as a member of the ‘gut-brain axis’ 
The human body is endowed with a complex physiological system that maintains relatively 
constant body weight and fat stores despite the wide variations in daily energy intake and 
energy expenditure. With weight loss, compensatory physiological adaptations result in 
increased hunger and decreased energy expenditure, while opposite responses are triggered 
when body weight increases. This regulatory system is formed by multiple interactions 
between the gastrointestinal tract (GIT), adipose tissue, and the CNS and is influenced by 
behavioural, sensorial, autonomic, nutritional, and endocrine mechanisms [2, 3]. 
The hypothalamus (particularly the ARC) and the brain (particularly the NTS) are the main 
sites of convergence and integration of the central and peripheral signals that regulate food 
intake and energy expenditure [193, 194]. There are mechanisms of short-term regulation 
(satiety signals) which determine the beginning and the end of a meal (hunger and satiation) 
and the interval between meals (satiety) [195], and long-term regulatory factors (signals of 
adiposity) which help the body to regulate energy depots. Thus, meal-generated satiety 
signals from the GIT do interact with longer-term adiposity signals, such as insulin and 
leptin in maintaining energy balance. Satiety signals from the GIT are transmitted primarily 
through vagal and spinal nerves to the NTS. There is, however, a large integration and 
convergence of these signals by neural connections between the ARC nucleus, NTS, and 
vagal afferent fibres. The nervous system, in turn, influences gastric and pancreatic exocrine 
secretion, gastrointestinal motility, blood supply, and secretion of gut hormones [191].  
The GIT contributes with several peptides that have incretin-, hunger-, and satiety-
stimulating actions, such as ghrelin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), 
oxyntomodulin (OXM), and cholecystokinin (CCK) and that are considered as members of 
the ‘gut-brain axis’. Many of the GIT hormones that affect food intake are also synthesized 
in the brain, such as CCK, GLP-1, apolipoprotein A-IV, gastrin-releasing peptide, PYY, and 
ghrelin. Generally, peptides that reduce (or increase) food intake when administered 
systemically usually have the same action when administered centrally. This has been 
demonstrated for CCK, GLP-1, apolipoprotein A-IV, gastrin-releasing peptide, neuromedin 
B, and ghrelin [5, 6, 191]. 
Ghrelin is expressed in a group of neurons adjacent to the third ventricle, between the 
DMN, VMN, PVN and ARC. These neurons terminate on NPY/AgRP, POMC and 
corticotrophin-releasing hormone neurons, and are able to stimulate the activity of ARC 
NPY neurons, forming a central circuit which could mediate energy homeostasis [17]. The 
central ghrelin neurons also terminate on orexin-containing neurons within the LHA [18], 
and icv administration of ghrelin stimulates orexin-expressing neurons [18, 196]. The 
feeding response to centrally administered ghrelin is attenuated after administration of anti-
orexin antibody and in orexin-null mice [18].  
Ghrelin reaches the hypothalamus through the circulation, and the brain stem through vagal 
innervation. The integrity of the vagus nerve is crucial for ghrelin effects since vagotomy 
prevents its orexigenic effect in animal models and humans. Ghrelin is thought to exert its 
orexigenic action via the ARC in a pattern representing a functional antagonism to leptin. c-
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Fos expression increases within ARC NPY-synthesizing neurons after peripheral 
administration of ghrelin [197], and ghrelin fails to increase food intake following ablation 
of the ARC [198]. Studies of knockout mice demonstrate that both NPY and AgRP signalling 
mediate the effect of ghrelin, although neither neuropeptide is obligatory [179]. GHS-R are 
also found on the vagus nerve [185], and administration of ghrelin leads to c-Fos expression 
in the area postrema and NTS [196, 199], suggesting that the brainstem may also participate 
in ghrelin signalling. The orexigenic action of ghrelin occurs independently of its 
stimulatory effects on GH secretion [176, 198, 200]. It is more likely that the physiological 
role of ghrelin is to prepare the body for an influx of metabolic energy [201-203]. 
Administration of ghrelin, either centrally or peripherally, increases food intake and body 
weight and decreases fat utilization in rodents [176, 204]. Furthermore, central infusion of 
anti-ghrelin antibodies in rodents inhibits the normal feeding response after a period of 
fasting, suggesting that ghrelin is an endogenous regulator of food intake [199]. Human 
subjects who receive ghrelin intravenously demonstrate a potent increase in food intake of 
28% [205], and rising pre-prandial levels correlate with hunger scores in humans initiating 
meals spontaneously [202]. Chronic administration increases body weight, not only by 
stimulating food intake, but also by decreasing energy expenditure and fat catabolism [165, 
176, 199]. 
In summary, the orexigenic effect of hypothalamic ghrelin is regulated through a neuronal 
network involving food intake. Fasting results in increased release of ghrelin from the 
stomach (the exact mechanism of this remains obscure) leading to increased plasma ghrelin 
levels, which reach the hypothalamus either via the blood stream directly in areas with no 
blood–brain barrier, or by crossing the blood–brain barrier via a saturable transport system 
or via the vagus nerve and the NTS [206]. Ghrelin's effect on appetite is mediated by an 
effect both on the hypothalamus and the NTS.To stimulate the release of the orexigenic 
peptides, ghrelin-containing neurons send efferent fibers onto NPY/AgRP-expressing 
neurons. On the other hand, to suppress the release of the anorexigenic peptide, ghrelin-
containing neurons send efferent fibers onto POMC neurons [17]. Leptin directly inhibits 
appetite-stimulating effects of NPY and AgRP, whereas hypothalamic ghrelin augments 
NPY gene expression and blocked leptin-induced feeding reduction. Thus, ghrelin and 
leptin have a competitive interaction in feeding regulation [188].  
Regulation of ghrelin secretion 
Serum ghrelin concentrations vary widely throughout the day. The most known factor for 
the regulation of ghrelin secretion is feeding [201] - ghrelin decreases after food intake, and 
increases when fasting with higher values during the night sleep [180, 201, 207]. In people 
on a fixed feeding schedule, circulating ghrelin levels are thought to be regulated by both 
calorie intake and circulating nutritional signals [162, 176]. Thus, blood glucose levels may 
play an important role in the regulation of ghrelin secretion: oral or intravenous 
administration of glucose decreases plasma ghrelin concentration [208].  Ghrelin levels fall 
in response to the ingestion of food, but not following gastric distension by water intake 
suggesting that mechanical distension of the stomach alone clearly does not induce ghrelin 
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release [176, 209, 210]. In healthy subjects, a longer fasting period during the day (i.e. 
irregular meal pattern typical for several eating disorders) increases ghrelin concentration, 
but does not affect postprandial ghrelin response to a mixed meal [211]. The described 
pattern of secretion raised the concept of ghrelin as a hunger hormone, responsible for meal 
initiation. However, one study has failed to show a correlation between the ghrelin level and 
the spontaneous initiation of a meal in humans [212], and an alteration of feeding schedule 
in sheep has been shown to modify the timing of ghrelin peaks [213]. Recently Schüssler et 
al. showed that ghrelin levels increased significantly during a 30-min. interval following a 
presentation of pictures with food in healthy volunteers and suggested that in addition the 
sight of food can elevate ghrelin levels [214]. 
The most remarkable inhibitory input on ghrelin secretion is represented by the activation of 
somatostatin (SS) receptors as indicated by evidence that native SS, its natural analog 
cortistatin, and a synthetic analog such as octreotide lower circulating ghrelin levels in 
humans [215]. Ghrelin secretion in humans is under the stimulatory control of the 
cholinergic, namely muscarinic receptors, and acetylcholine is the first stimulatory 
neurotransmitter shown to play a stimulatory role on ghrelin secretion in humans [216]. 
In rats, ghrelin shows a bimodal peak, which occurs at the end of the light and dark periods 
[217]. In humans, ghrelin levels vary diurnally in phase with leptin, which is high in the 
morning and low at night [201].  
It should be considered that ghrelin secretion may be a conditioned response which occurs 
to prepare the metabolism for an influx of calories. But, whatever the precise physiological 
role of ghrelin, it appears not to be an essential regulator of food intake, as ghrelin-null 
animals do not have significantly altered body weight or food intake on a normal diet [218]. 
Relationship between ghrelin and glucose-insulin homeostasis  
Current extensive study data of ghrelin’s role in metabolic processes indicate its 
unambiguous relation with control on glucose homeostasis and β-cell function. Both GHS-
R1a and GHS-R1b are present in animal and human endocrine pancreas [219, 220]. Ghrelin 
is also present in pancreas, and epsilon pancreatic cells have been suggested to be a putative 
ghrelin-expressing cell type [221]. Moreover, a specific receptor able to bind both acylated 
and nonacylated ghrelin has also been demonstrated within the human pancreas; this is 
therefore a non-GHS-R1a [168, 222]. Ongoing studies support the hypothesis that ghrelin, 
independently of its acylation, modulates glucose metabolism at the hepatic level [223].  
Exogenic ghrelin short-tem effects induce hyperglycaemia in experimental rodents via an GH-
independent mechanism of action [224]. In contrast, ghrelin-receptor antagonists may 
improve glucose tolerance in rats, with no weight gain due to increased insulin secretion 
[225]. Acute administration of ghrelin to humans increases plasma glucose levels and 
amplifies the hyperglycaemic effect of arginine [226]. This hyperglycaemic effect might 
result from the endocrine effects of ghrelin as well as from direct effects on hepatocytes in 
which it modulates glycogen synthesis and gluconeogenesis [227]. Although data of ghrelin 
long-term effects are insufficiently clarified, a tendency of an increase in plasma glucose levels 
 Insulin Resistance 110 
appears to be presented [224]. Many of the studies in patients with type 1 diabetes show low 
ghrelin levels, probably as a manifestation of a compensatory mechanism against 
hyperglycaemia [225]. 
Numerous studies indicate a negative association between systemic ghrelin and insulin 
levels [184, 228]. Thus, ghrelin is found to inhibit insulin secretion both in vitro and in vivo in 
most human and animal studies [226, 229]. In humans the acute administration of ghrelin 
inhibits spontaneous and arginine-stimulated insulin secretion but does not affect the 
insulin response to the oral glucose tolerance test (OGTT) [226, 230, 231]. In addition, the 
regulation of insulin secretion by ghrelin is closely related to the blood glucose level. Date et 
al. [232] reported that ghrelin stimulates insulin release in the presence of high levels of 
glucose (8.3mM) that could independently cause insulin release from cultured islet cells. In 
contrast, ghrelin had no effect on insulin release in the context of a basal level of glucose (2.8 
mM) [232]. Antagonism of the pancreatic ghrelin can enhance insulin release to meet 
increased demand for insulin in high-fat diet-induced obesity of mice [233].  
Ghrelin might influence some of the peripheral effects of insulin. Thus, it is found to 
stimulate hepatic glucose production [227], reinforce the action of insulin on glucose 
disposal in mice [234], inhibit adinopectin secretion [235] and stimulate secretion of the 
counter-regulatory hormones, including GH, cortisol, adrenaline [236] and possibly 
glucagon [237]. In healthy subjects, in the absence of GH and cortisol secretion, ghrelin 
acutely decreased peripheral, but not hepatic, insulin sensitivity together with stimulation of 
lipolysis. These effects occurred without detectable suppression of AMP-activated protein 
kinase phosphorylation (an alleged second messenger for ghrelin) in skeletal muscle [238]. 
So, ghrelin also exerts direct metabolic effects towards induction of insulin resistance 
independent of the regulation by counter-regulatory hormones.  
Insulin in turn decreases ghrelin levels, regardless of changes in glucose concentrations  
[239]. Broglio et al. [240] have found that both oral and intravenous insulin suppress ghrelin, 
although they exhibit opposite effects on glucose levels. The same authors have shown that 
protein-induced inhibition of ghrelin is enabled by oral administration, while intravenous 
arginine does not lead to ghrelin reduction regardless of insulin elevations, which is a fact of 
interest and of relation to protein diets [240]. 
Given all the above data, it is proposed that ghrelin could have an important function in 
glucose homeostasis and insulin release, independent of GH secretion [241]. Data of 
administration of GHSR1a antagonists suggest that these compounds improve long-term 
glucose tolerance and insulin resistance. Since there are some differences about the role of 
ghrelin on insulin secretion [188], further research on ghrelin-insulin interrelationship is 
expected. At least theoretically, ghrelin and/or its signalling manipulation could be used for 
the treatment or prevention of diseases of glucose homeostasis. 
Ghrelin in obesity, diabetes mellitus and metabolic syndrome 
In addition to a probable role in meal initiation, ghrelin seems to be an adiposity-related 
hormone that is involved in the long-term regulation of body weight Plasma ghrelin levels 
are inversely correlated with body mass index and current evidence strongly suggests that 
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ghrelin could contribute to obesity and the metabolic syndrome [225]. Variations within the 
ghrelin gene may contribute to early-onset obesity [242, 243] or be protective against fat 
accumulation [225], but the role of ghrelin polymorphisms in the control of body weight 
continues to be controversial [244, 245].  
It has been shown that ghrelin secretion differs between lean and obese subjects. Thus, 
plasma ghrelin concentration is found to be low in obese people and high in lean people in 
some studies [207, 208, 246]. The expression of ghrelin receptors in the hypothalamus 
increases markedly with either fasting or chronic food restriction [247], as does the 
hypothalamic response to a ghrelin-receptor agonist [248], which is consistent with a feed-
forward loop that enhances ghrelin-mediated stimulation of appetite during energy deficit. 
Anorexic individuals have high circulating ghrelin which falls to normal levels after weight 
gain [249]. The suppressed plasma ghrelin levels in obese subjects normalize after diet-
induced weight loss [250]. The postprandial falls of serum ghrelin concentrations are 
proportional to energy intake in lean subjects, but not in obese subjects. Unlike lean 
individuals, obese subjects do not demonstrate the same rapid post-prandial drop in ghrelin 
levels [251]. Moreover, obesity is associated with much lower overall reduction of 
postprandial ghrelin levels and an absence of nocturnal elevations as seen in subjects of 
normal weight [194, 195, 210]. This may result in increased food intake and contribute to 
obesity.  The fall in plasma ghrelin concentration after bariatric surgery, despite weight loss, 
is thought to be partly responsible for the suppression of appetite and weight loss seen after 
these operations [252].  
The severe hyperphagia seen in Prader–Willi syndrome is associated with elevated ghrelin 
levels [253] that is in contrast to other forms of obesity, and it has been hypothesized that 
ghrelin might contribute to the nature of this syndrome. Moreover, there are similarities 
between the clinical features of Prader–Willi syndrome and those predicted from 
overstimulation of NPY by ghrelin (e.g. hyperphagic obesity, hypogonadotropic 
hypogonadism and dysregulation of GH) and the correlation between ghrelin levels and 
hyperphagia and excessive obesity, in these patients [254]. Indeed, the high ghrelin levels in 
obese people with Prader–Willi syndrome make the carriers of the syndrome logical first-
line candidates for testing the weight reducing effects of ghrelin-blocking agents 
Recently, the role of ghrelin in diabetes mellitus has been investigated: polymorphisms of 
the ghrelin gene are associated with the risk of diabetes [255], ghrelin promotes regeneration 
of b-cells in streptozocin-treated newborn rats, preventing the development of diabetes in 
disease-prone animals after b-cell destruction [256], and ghrelin antagonists partially reverse 
hyperphagia in uncontrolled, streptozocin-diabetic rats [257]. It has been found that fasting 
ghrelin concentrations are lower in people with type 2 diabetes mellitus than in non-diabetic 
people, even after adjusting for BMI. It has also been shown that the decrease in circulating 
ghrelin is proportionate to the degree of insulin insensitivity. We also found significant 
negative correlation between ghrelin and fasting insulin, and HOMA-index, respectively, in 
insulin resistant women with type 2 diabetes mellitus [258]. These observations suggest that 
ghrelin and insulin sensitivity are linked. All the data indicate that ghrelin might have a role 
in the pathogenesis and therapy of diabetes, contributing to either the impairment of insulin 
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sensitivity or to the restraint of body-mass gain. Nonetheless, because of the controversy 
about the cause-and-effect relationship between ghrelin levels and diabetes mellitus, further 
investigations are needed to elucidate the precise role of ghrelin (and its variants) in the 
development and treatment of this disease.  
Low plasma ghrelin levels are associated with metabolic cluster per se, which indicates that 
ghrelin might be a useful biomarker for the metabolic syndrome [228, 259]. Thus, conditions 
of severe metabolic syndrome due to insulin resistance, such as in obese Pima Indians, are 
related with reduced fasting ghrelin plasma levels [207]. In a study on the relation between 
metabolic parameters, ghrelin, leptin and IGF-1 in a cohort of 1,045 individuals, Ukkola et al. 
[260] have found that low ghrelin levels are associated with metabolic syndrome and type 2 
diabetes mellitus only in presence of insulin and leptin resistance. At high leptin levels, 
ghrelin concentrations decrease linearly with increasing the number of metabolic syndrome 
components [260]. In patients on haemodialysis, fasting ghrelin levels negatively correlate 
with metabolic syndrome manifestation, ghrelin shows a tendency to decrease with 
increasing the number of the metabolic syndrome components, and the waist circumference 
appears to be an independent predictor of its levels [261]. 
In patients with the metabolic syndrome and low ghrelin levels, intraarterial administration 
of ghrelin rapidly improves endothelial function [262]. Similar to insulin, ghrelin stimulates 
an increased nitrogen oxide (NO) production in cultured bovine aortic endothelial cells in a 
dose- and time-dependent manner. It has been found that ghrelin-induced NO production 
in human aortic endothelial cells is arrested by their pre-treatment with a NO-synthase 
inhibitor, phosphatidylinositol synthase (PI 3)-kinase inhibitor, selective GHSR-1а 
antagonist or “exclusion” of these receptors. On the other hand, ghrelin has been found to 
stimulate enhanced phosphorylation of Akt (Ser473) and endothelial NO-synthase in human 
aortic endothelial cells, as well as phosphorylation of mitogen-activated protein (МАР) 
kinase, but not of МАР-kinase-dependent production of the vasoconstrictor endothelin-1 in 
bovine aortic endothelial cells. With regard to these data it may be concluded that ghrelin 
exhibits characteristic, rapid vascular effects, presented as stimulated NO production in the 
endothelium via signal pathways including the GHSR-1a, PI 3-kinase, Akt and endothelial 
NO-synthase, which may be taken into consideration for the development of innovative 
therapeutic strategies for endothelial dysfunction in diabetes and insulin resistance [262]. 
Vlasova et al. have found that peripheral injection of a ghrelin antagonist in experimental 
animals (rats) increases arterial pressure and pulse rate via at least partial activation of the 
sympathetic nervous system [263]. These findings direct our attention to eventual 
cardiovascular adverse effects, when administering ghrelin antagonists as a therapeutic 
strategy for reducing food intake, particularly in patients at a high cardiovascular (CV) risk 
(e.g., patients with metabolic syndrome). 
Ghrelin’s role in processes of reproduction and PCOS 
Presently not so much is known of ghrelin effects on processes of reproduction. 
Experimental models in rats have shown that ghrelin plays a role at different levels of the 
hypothalamic-pituitary-ovary axis regulation. Its central route of administration in female 
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rats results in suppression of the LH secretion at various stages of estrus [264]. In in vitro 
settings, ghrelin also inhibits gonadotropin-releasing hormone (GnRH) secretion from the 
hypothalamus [264]. At a pituitary level, ghrelin exhibits either stimulating or inhibiting 
action on basal LH secretion, depending on the menstrual cycle stage. However, the in vitro 
GnRH-stimulated LH release is inhibited by ghrelin, regardless of the steroid medium [265]. 
In rhesus monkeys, the confirmed inhibitory effect of ghrelin on the GnRH-LH system 
suggests that in primates, ghrelin exhibits a central regulatory effect on processes of 
reproduction [266].  
It was shown by Kluge et al. that ghrelin suppresses the secretion of LH and FSH in healthy 
women [267]. Ghrelin levels have been found to be higher in anovulatory women with 
excessive physical loading-induced anorexia nervosa and amenorrhea, as well as in normal 
weight-women with hypothalamic amenorrhea [268-270]. In normal-weight women with 
amenorrhea, the increased ghrelin levels have been associated with disturbed dietary habits 
and regimen [271]. It is not clear whether disturbances in ghrelin secretion play a direct role 
in neuroendocrine regulation of the hypothalamic-pituitary-ovary axis or present a marker 
of the metabolic status itself.  
In males, ghrelin has an additional inhibitory role, decreasing human chorionic 
gonadotropin (hCG)- and cAMP-stimulated testosterone secretion [272] and the expression 
of the gene encoding stem cell factor that is a key mediator of spermatogenesis and a 
putative regulator of Leydig-cell development [273]. In hypogonadal males, a positive 
correlation between ghrelin and androgens persists after testosterone replacement therapy 
[274]. 
There is no consensus on whether alterations in levels of appetite-regulating hormones, such 
as ghrelin, are associated with PCOS. Fasting ghrelin levels were found decreased in most 
[275-279], but not in all studies [280, 281] in women with PCOS. Thus in 2002, Pagotto et al. 
[275] first demonstrated that ghrelin levels were lower in obese women with PCOS, 
compared with these in weight-matched healthy controls. Ghrelin has been inversely 
correlated with insulin resistance markers. These correlations have persisted even after 
therapy (hypocaloric diet plus metformin or placebo) for improving insulin sensitivity. In 
both groups, weight reduction has resulted in minimal changes of plasma ghrelin levels. 
The observed negative correlation between ghrelin and androstenedione, but not between 
ghrelin and testosterone or other androgens, is interesting [275]. In PCOS, Schofl et al. have 
confirmed lower ghrelin levels that are in a close correlation with insulin resistance rates 
[276]. After therapy with metformin in insulin-resistant women, ghrelin levels have 
increased, but in insulin-sensitive women with PCOS, ghrelin levels have been comparable 
to these in controls. Furthermore, the authors have found no correlation between ghrelin 
and the body mass index (BMI) [276], which suggests a ghrelin-insulin resistance 
interrelation apart from ghrelin activity in controlling appetite, body weight, respectively. 
Panidis et al. [282] have reported that women with PCOS and hyperandrogenaemia have 
significantly lower ghrelin levels compared to healthy controls and PCOS carriers with 
clinical hyperandrogenism but normal androgen levels. Ghrelin levels in the latter are lower 
than these found in the control group, but the differences are not statistically significant. The 
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authors have concluded that PCOS-associated hyperandrogenaemia results in reduced 
ghrelin concentrations [282]. Although PCOS-associated hyperandrogenaemia and 17-OH-
progesterone levels are inversely related to ghrelin levels, anovulation and polycystic ovary 
morphology are associated with higher ghrelin concentrations [283]. Thus, it has been 
hypothesized that different clinical and biochemical manifestations of the syndrome might 
be associated with different concentrations of ghrelin. 
In support of the relation between PCOS and ghrelin, there are data of increased ghrelin 
levels after a 3-month treatment with an oral contraceptive containing both ethinyl 
oestradiol and drospirenone in women with PCOS [284]. Similar to other studies, ghrelin is 
negatively correlated with the BMI, waist/hip ratio, insulin, homeostatic model assessment 
(HOMA) index and free testosterone [284]. According to a study conducted by Fusco et al., 
ghrelin administration in normal weight-women and obese PCOS patients has exerted 
glucose-enhancing and insulin-lowering effects, the latter absent in the normal weight-
controls [285], which supports the relation between ghrelin and hormonal/metabolic 
disorders in PCOS. 
One of studies that have not confirmed changes in ghrelin levels in women with PCOS is 
this conducted by Orio et al. [280]. The authors have found no correlation between ghrelin 
and either of the hormonal or biochemical parameters (including insulin and insulin 
resistance markers), but only a correlation between ghrelin and the BMI [280]. These data 
support the relation determined between ghrelin and the body weight only and exclude the 
effects of the disease itself. These findings are in a sense similar to those observed by Bik et 
al., who have not found significant differences in ghrelin levels between a group of normal 
weight PCOS women and a group of normal weight healthy women; however, ghrelin was 
significantly lower in healthy obese women compared to lean women with PCOS [286]. 
Impaired ghrelin suppression after a test meal and increased feeling of hunger and 
decreased feeling of satiety (according to visual analogue scales) have been described in a 
small group of obese women with PCOS, even after weight reduction [287], which has been 
also confirmed by another study, comparing lean and obese women with PCOS and 
relevant, weight-matched controls [288]. Romualdi et al. [289] gave more detailed evaluation 
of ghrelin and polypeptide YY responses following oral load with a test meal (527 kcal, 
distributed by contents in 24.1% fats, 54.4% carbohydrates and 21.5% proteins) in women 
with PCOS. Low baseline ghrelin levels and reduced suppression after meals, more 
pronounced in the obese than in the lean patients was shown. The authors have found no 
correlation between ghrelin and the androgens; however, a negative correlation has been 
established between ghrelin and the НОМА-index. Compared to controls, PCOS women 
had a significantly suppressed neuropeptide Y response to injected ghrelin, as the response 
has restored after treatment with metformin and significant insulin reduction. In this 
experimental setting, leptin has undergone no significant changes [289]. Obviously, 
hyperinsulinaemia is the factor which exerts effect on the ghrelin-neuropeptide Y relation. 
We found significantly lower ghrelin levels in women with PCOS compared to healthy 
controls (21.78 ± 2.12 ng/ml versus 34.67 ± 3.57 ng/ml; p = 0.04), as ghrelin was inversely 
correlated with insulin levels at a degree similar to these of insulin resistance markers. 
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Negative correlations were also found with the BMI, waist measurement and waist-to-hip 
ratio, in conformity with most of the studies at present. Furthermore, the observed negative 
correlation between ghrelin and testosterone (r = −0.315; p < 0.05), and this between ghrelin 
and leptin (r = −0.306; p<0.05) disappear after the exclusion of BMI, waist-to-hip ratio and 
HOMA-index [290]. In a comparative study on ghrelin levels in insulin-resistant women 
with PCOS and women with type 2 diabetes and higher insulin resistance, ghrelin levels 
have been significantly lower in syndrome carriers versus diabetics [291]. Based on our data 
we consider that ghrelin levels in women with PCOS reflect both the metabolic and 
hormonal disturbances, typical for the syndrome. 
A recent study conducted by Panidis et al. [292] has confirmed that alterations in ghrelin 
secretion are intrinsic for the disease itself and has demonstrated that active (acetylated) 
ghrelin/total ghrelin ratio is decreased in normal weight-women with PCOS, as the 
anomalies are most pronounced in the severe forms of the syndrome, including all 
diagnostic criteria: hyperandrogenia, chronic anovulation and morphologically polycystic 
ovaries [292]. Based on the proven changes in women with PCOS and various phenotype 
manifestations, some authors have even suggested ghrelin to be used as a predictive marker 
of PCOS and have found through a plot-analysis of the receiver operating characteristic 
curve (ROC) a sensitivity of 70% and specificity of 86% with a cut-off value of 34.1 ng/ml, 
below which the diagnosis of PCOS is likely, while a cut-off ghrelin value below 9 ng/ml is 
highly specific for PCOS [293].  
In conclusion, there is, probably, an anomaly in ghrelin regulation in PCOS, related not only 
to overweight and insulin resistance. The mechanisms associating abnormal ghrelin 
regulation with the disease are still to be elucidated. However, the pathological and 
therapeutic importance of this association is unclear. Independent effects of ghrelin on the 
hypothalamic-pituitary-gonadal axis with an inhibitory effect on the LH secretion and a 
decreased LH response to GnRH, typical for the syndrome, may also be taken into 
consideration. 
4. Conclusion 
Given the growing epidemic of obesity, it has become increasingly important to understand 
the physiological processes that regulate body weight. Regulation of food intake and 
metabolism is maintained by complex pathways and neuronal circuits which themselves 
receive peripheral signals such as gut hormones. Metabolically important abdominal obesity 
with an excess of visceral fat accumulation results in altered release of adipokines, leading 
to CNS mediated skeletal muscle and hepatic insulin resistance. The central regulation of 
energy balance has become even more fascinating and complex with the characterization of 
mechanisms of action of NPY, the most abundant hypothalamic orexigenic factor. Much 
attention has recently centered on ghrelin, the only known circulating orexigen. Insulin 
resistance and compensatory hyperinsulinemia are independently associated with 
suppression of ghrelin that furthers our understanding of the variable expression of ghrelin 
in humans.  
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With continued research, it should be possible to elucidate exactly how the associations 
among insulin resistance, hyperinsulinemia, and orexigens (NPY and ghrelin) participate in 
the more intricate web of factors that regulate body weight. Better understanding of the 
mechanisms involved in the regulation of energy metabolism will become a background for 
development of new therapeutic approaches against obesity, insulin resistance, metabolic 
syndrome, and other nutritional disorders. 
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